UltiPace™ Pacing Lead

Robust Stylet-Driven Leads for Left Bundle Branch Area Pacing

Pioneering Innovation in LBBAP

Experience the innovation of the UltiPace Pacing Lead, Abbott's latest breakthrough, and the only approved stylet-driven lead for left bundle branch area pacing (LBBAP) with a robust distal lead tip design.* Engineered for superior performance in the pursuit of continuous innovation.1

UltiPace cross section

Proven Design Evolved

UltiPace cross section

vs. Tendril STS1

3X

Increase in abrasion resistance

3.5X

Increase in lead crush resistance

vs. Tendril MRI 1

2.2X

Increase in abrasion resistance

2.6X

Increase in lead crush resistance

Demonstrated LBBAP Success and Safety


Composite
success
rate2**

93% circle

of patients not experiencing
LBBAP-related adverse effects at  6 months post-implant.2

99.5% circle

Resistant to Distal Fatigue Failure

UltiPace Pacing Leads have a robust distal lead tip without a flexible zone that helps reduce stress on the conductors and the chance for distal fatigue failure compared to competitive leads.3

Ulipace pacing leads

Zero Helix Retraction

The Helix Locking Tool is a proven solution to lock an extended helix during tissue burrowing without retraction.3

UltiPace cross section

The Helix Locking Tool aids with lead fixation by providing control over the extension and retraction of the helix.

The Helix Locking Tool helps deploy the active fixation helix and hold it in place

Improved Torque Transmission with Fewer Rotations

 

Improvement in torsional stiffness when using UltiPace Pacing Leads compared to LBBAP-approved lumenless pacing leads.3

94% circle

Torque being applied to UltiPace Pacing Lead body in LBBAP procedure.

Ensuring optimal slack during stylet retraction is key to preventing complications


Continuous Unipolar Pacing and Impedance Monitoring

Provides the user with uninterrupted feedback to help achieve optimal results.4

References

*Robust distal lead tip without a flexible zone in distal 14.5 mm, CE and FDA Approval for LBBAP.
**Composite success rate of acceptable capture thresholds and sense amplitudes for LBBAP at 6 months post-implant.

  1. Abbott. Data on File. Item: 91010074 Ver A.
  2. Abbott. Data on File.
  3. Abbott. Data on File, Engineering Technical Report. Item: 90994484 Ver D.
  4. Burri, H., Jastrzebski, M., Cano, O., Curila, K., Pooter, J. de, Huang, W., Israel, C., Joza, J., Romero, J., Vernooy, K., Vijayaraman, P., Whinnett, Z., & Zanon, F. (2023). EHRA clinical consensus statement on conduction system pacing implantation: Executive summary. endorsed by the Asia-Pacific Heart Rhythm Society (APHRS), Canadian heart rhythm society (CHRS) and Latin-American heart rhythm society (LAHRS). Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. https:// pubmed.ncbi.nlm.nih.gov/37061850/

Indications:

The UltiPace™ leads are indicated for use in combination with a compatible pacemaker, implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy (CRT ‑P/CRT ‑D) device to provide sensing and pacing for the management of chronic symptomatic bradycardia and various atrioventricular conduction abnormalities in patients who experience syncope, presyncope, fatigue, or disorientation due to arrhythmia/bradycardia, or any combination of these symptoms. The UltiPace leads are implanted transvenously in either the right atrium, the right ventricle or the left bundle branch area.

For indications for the pacing system, please refer to the applicable pulse generator manual.

MAT-2411896 v1.0